DNA 합성 시장 규모, 점유율, 성장 및 세계 산업 분석 : 종류별, 용도별, 지역별 인사이트와 예측(2026-2034년)

Growth Factors of DNA synthesis Market

The global DNA synthesis market is witnessing significant growth driven by the rising demand for synthetic DNA in research, diagnostics, and therapeutic applications. According to Fortune Business Insights, the market was valued at USD 5.19 billion in 2025, and it is expected to grow to USD 5.95 billion in 2026. With an anticipated CAGR of 19.09% from 2026 to 2034, the market is projected to reach USD 24.06 billion by 2034, reflecting the increasing adoption of synthetic DNA for gene therapy, molecular diagnostics, and personalized medicine. North America dominated the market in 2025, holding 54.61% market share, due to robust R&D infrastructure, high adoption of precision medicine, and active initiatives by leading companies to expand services and launch innovative products.

DNA synthesis involves the artificial creation of DNA molecules, including oligonucleotides, genes, and DNA fragments. These synthetic DNA products enable the development of new drugs, vaccines, gene therapies for genetic disorders, and molecular diagnostic tools such as PCR assays and nucleic-acid-based sensors. The rising prevalence of chronic, genetic, and rare diseases, along with increased healthcare expenditure and awareness of personalized treatment, is propelling demand for synthetic DNA globally.

Market Trends

Technological advancements have been a significant driver of market growth. Companies are focusing on faster, more accurate, and cost-effective DNA synthesis methods, including automated microfluidics systems, which reduce turnaround time and labor requirements. For example, in August 2023, Atantares raised USD 13.9 million to develop molecular chips for high-throughput enzymatic DNA synthesis, demonstrating the trend toward automation and efficiency.

During the COVID-19 pandemic, demand for synthetic DNA surged due to the urgent need for molecular diagnostic tests and vaccine development. Post-pandemic, the market stabilized, but the increased focus on precision medicine and gene-based therapeutics has maintained strong growth momentum.

Market Growth Factors

The growing use of DNA synthesis in novel therapeutics, molecular diagnostics, and R&D initiatives is driving market expansion. Gene synthesis is particularly in demand due to its customizable applications for pharmaceutical and biotechnology companies. For instance, the gene synthesis segment accounted for 74.31% of the market in 2026. Oligonucleotide synthesis is also gaining traction due to its use in diagnostics, therapeutics, and gene therapy.

Healthcare spending and investments in precision medicine are further enhancing market growth. Gene synthesis allows tailored treatments for diseases such as cancer and genetic disorders, aligning with government initiatives in countries like the U.K., where public R&D spending is projected to reach USD 27.36 billion by 2025.

Market Restraints

Despite rapid growth, the market faces challenges, including a lack of clear regulatory frameworks and a shortage of skilled laboratory personnel. For instance, in September 2022, the European Medicines Agency highlighted the need for guidelines on synthetic oligonucleotides, reflecting regulatory uncertainties that may slow product launches.

Segmentation Analysis

By Product & Service: The services segment dominated the market with 72.76% share in 2026, driven by providers offering high-purity, cost-effective, and customized DNA solutions. The products segment, including instruments and reagents & consumables, also holds a significant portion, bolstered by new launches such as the BioXp Select DNA Cloning kit by Telesis Bio Inc. in May 2023.

By Type: Gene synthesis holds the largest share due to customizable sequences and high demand from research institutions and industry. Oligonucleotide synthesis is growing due to increasing use in diagnostics, therapeutics, and molecular biology applications.

By Application: The diagnostics segment dominated in 2026 with 50.26% market share, driven by molecular diagnostics for diseases such as cancer and infectious diseases. The therapeutics segment is growing due to gene therapy and vaccine development, while R&D continues to expand through drug discovery, cloning, and gene editing initiatives.

By End-User: Pharmaceutical and biotechnology companies hold the largest share, leveraging synthetic DNA for novel therapeutics and gene therapy development. Contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) follow closely, offering specialized production and services. Academic and research institutes are also increasing adoption.

Regional Insights

North America dominated with USD 2.83 billion in 2025, growing to USD 3.22 billion in 2026, driven by high prevalence of chronic and genetic diseases, advanced research infrastructure, and increasing personalized medicine initiatives. The U.S. market alone is projected at USD 3.03 billion in 2026. Europe holds a significant market share, with the U.K. and Germany projected to reach USD 0.22 billion and USD 0.32 billion, respectively, in 2026, supported by strong R&D collaborations. The Asia Pacific region is anticipated to witness the highest CAGR, with China, Japan, and India projected at USD 0.43 billion, USD 0.24 billion, and USD 0.13 billion, respectively, in 2026, due to growing biotech infrastructure, research collaborations, and increasing adoption of synthetic DNA technologies. Latin America and the Middle East & Africa are expected to grow moderately, driven by government initiatives to enhance biotechnology research.

Key Players & Developments

Prominent market players include Thermo Fisher Scientific, Integrated DNA Technologies, GenScript, Eurofins Scientific, Azenta, and Twist Bioscience. Companies focus on strategic collaborations, facility expansions, and new service launches. For instance, in November 2023, Twist Bioscience launched Twist Express Genes, offering rapid gene synthesis with accelerated delivery.

Conclusion

The global DNA synthesis market is set for robust growth, expanding from USD 5.19 billion in 2025 to USD 24.06 billion by 2034, driven by technological advancements, growing demand in diagnostics, therapeutics, and research, and increasing investments in synthetic biology. With innovations in gene synthesis, growing adoption of oligonucleotides, and regional expansion, the market is poised to play a critical role in precision medicine and the future of biotechnology worldwide.

Segmentation By Product & Service

• Products
  • Instruments
  • Reagents & Consumables
• Services

By Type

• Oligonucleotide Synthesis
• Gene Synthesis

By Application

• Diagnostics
  • Infectious Diseases
  • Cancer
  • Others
• Therapeutics
  • Gene Therapy
  • Preventive Medicine
  • Others
• Research & Development
  • Cloning and Gene Editing
  • Drug Discovery & Development
  • Others

By End-user

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs) & Contract Development and Manufacturing Organizations (CDMOs)
• Others

By Region

• North America (By Product & Service, By Type, By Application, By End-user, and By Country)
  • U.S.
  • Canada
• Europe (By Product & Service, By Type, By Application, By End-user, and By Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product & Service, By Type, By Application, By End-user, and By Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product & Service, By Type, By Application, By End-user, and By Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product & Service, By Type, By Application, By End-user, and By Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Technological Developments in the DNA Synthesis
• 4.2. Key Industry Developments - Mergers, Acquisitions, Partnerships, etc.
• 4.3. New Product Launches
• 4.4. Impact of COVID-19 on the DNA Synthesis Market

5. Global DNA Synthesis Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product & Service
  • 5.1.1. Products
    • 5.1.1.1. Instruments
    • 5.1.1.2. Reagents & Consumables
  • 5.1.2. Services
• 5.2. Market Analysis, Insights and Forecast - By Type
  • 5.2.1. Oligonucleotide Synthesis
  • 5.2.2. Gene Synthesis
• 5.3. Market Analysis, Insights and Forecast - By Application
  • 5.3.1. Diagnostics
    • 5.3.1.1. Infectious Diseases
    • 5.3.1.2. Cancer
    • 5.3.1.3. Others
  • 5.3.2. Therapeutics
    • 5.3.2.1. Gene Therapy
    • 5.3.2.2. Preventive Medicine
    • 5.3.2.3. Others
  • 5.3.3. Research & Development
    • 5.3.3.1. Cloning and Gene Editing
    • 5.3.3.2. Drug Discovery & Development
    • 5.3.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Pharmaceutical & Biotechnology Companies
  • 5.4.2. Contract Research Organizations (CROs) & Contract development and manufacturing organizations (CDMOs)
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America DNA Synthesis Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product & Service
  • 6.1.1. Products
    • 6.1.1.1. Instruments
    • 6.1.1.2. Reagents & Consumables
  • 6.1.2. Services
• 6.2. Market Analysis, Insights and Forecast - By Type
  • 6.2.1. Oligonucleotide Synthesis
  • 6.2.2. Gene Synthesis
• 6.3. Market Analysis, Insights and Forecast - By Application
  • 6.3.1. Diagnostics
    • 6.3.1.1. Infectious Diseases
    • 6.3.1.2. Cancer
    • 6.3.1.3. Others
  • 6.3.2. Therapeutics
    • 6.3.2.1. Gene Therapy
    • 6.3.2.2. Preventive Medicine
    • 6.3.2.3. Others
  • 6.3.3. Research & Development
    • 6.3.3.1. Cloning and Gene Editing
    • 6.3.3.2. Drug Discovery & Development
    • 6.3.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Pharmaceutical & Biotechnology Companies
  • 6.4.2. Contract Research Organizations (CROs) & Contract development and manufacturing organizations (CDMOs)
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe DNA Synthesis Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product & Service
  • 7.1.1. Products
    • 7.1.1.1. Instruments
    • 7.1.1.2. Reagents & Consumables
  • 7.1.2. Services
• 7.2. Market Analysis, Insights and Forecast - By Type
  • 7.2.1. Oligonucleotide Synthesis
  • 7.2.2. Gene Synthesis
• 7.3. Market Analysis, Insights and Forecast - By Application
  • 7.3.1. Diagnostics
    • 7.3.1.1. Infectious Diseases
    • 7.3.1.2. Cancer
    • 7.3.1.3. Others
  • 7.3.2. Therapeutics
    • 7.3.2.1. Gene Therapy
    • 7.3.2.2. Preventive Medicine
    • 7.3.2.3. Others
  • 7.3.3. Research & Development
    • 7.3.3.1. Cloning and Gene Editing
    • 7.3.3.2. Drug Discovery & Development
    • 7.3.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Pharmaceutical & Biotechnology Companies
  • 7.4.2. Contract Research Organizations (CROs) & Contract development and manufacturing organizations (CDMOs)
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific DNA Synthesis Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product & Service
  • 8.1.1. Products
    • 8.1.1.1. Instruments
    • 8.1.1.2. Reagents & Consumables
  • 8.1.2. Services
• 8.2. Market Analysis, Insights and Forecast - By Type
  • 8.2.1. Oligonucleotide Synthesis
  • 8.2.2. Gene Synthesis
• 8.3. Market Analysis, Insights and Forecast - By Application
  • 8.3.1. Diagnostics
    • 8.3.1.1. Infectious Diseases
    • 8.3.1.2. Cancer
    • 8.3.1.3. Others
  • 8.3.2. Therapeutics
    • 8.3.2.1. Gene Therapy
    • 8.3.2.2. Preventive Medicine
    • 8.3.2.3. Others
  • 8.3.3. Research & Development
    • 8.3.3.1. Cloning and Gene Editing
    • 8.3.3.2. Drug Discovery & Development
    • 8.3.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Pharmaceutical & Biotechnology Companies
  • 8.4.2. Contract Research Organizations (CROs) & Contract development and manufacturing organizations (CDMOs)
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America DNA Synthesis Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product & Service
  • 9.1.1. Products
    • 9.1.1.1. Instruments
    • 9.1.1.2. Reagents & Consumables
  • 9.1.2. Services
• 9.2. Market Analysis, Insights and Forecast - By Type
  • 9.2.1. Oligonucleotide Synthesis
  • 9.2.2. Gene Synthesis
• 9.3. Market Analysis, Insights and Forecast - By Application
  • 9.3.1. Diagnostics
    • 9.3.1.1. Infectious Diseases
    • 9.3.1.2. Cancer
    • 9.3.1.3. Others
  • 9.3.2. Therapeutics
    • 9.3.2.1. Gene Therapy
    • 9.3.2.2. Preventive Medicine
    • 9.3.2.3. Others
  • 9.3.3. Research & Development
    • 9.3.3.1. Cloning and Gene Editing
    • 9.3.3.2. Drug Discovery & Development
    • 9.3.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Pharmaceutical & Biotechnology Companies
  • 9.4.2. Contract Research Organizations (CROs) & Contract development and manufacturing organizations (CDMOs)
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa DNA Synthesis Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product & Service
  • 10.1.1. Products
    • 10.1.1.1. Instruments
    • 10.1.1.2. Reagents & Consumables
  • 10.1.2. Services
• 10.2. Market Analysis, Insights and Forecast - By Type
  • 10.2.1. Oligonucleotide Synthesis
  • 10.2.2. Gene Synthesis
• 10.3. Market Analysis, Insights and Forecast - By Application
  • 10.3.1. Diagnostics
    • 10.3.1.1. Infectious Diseases
    • 10.3.1.2. Cancer
    • 10.3.1.3. Others
  • 10.3.2. Therapeutics
    • 10.3.2.1. Gene Therapy
    • 10.3.2.2. Preventive Medicine
    • 10.3.2.3. Others
  • 10.3.3. Research & Development
    • 10.3.3.1. Cloning and Gene Editing
    • 10.3.3.2. Drug Discovery & Development
    • 10.3.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By End User
  • 10.4.1. Pharmaceutical & Biotechnology Companies
  • 10.4.2. Contract Research Organizations (CROs) & Contract development and manufacturing organizations (CDMOs)
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Thermo Fisher Scientific Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Integrated DNA Technologies, Inc. (Danaher)
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Eurofins Scientific
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. GenScript
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Azenta, Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. LGC Limited
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Biomatik
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Telesis Bio Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Twist Bioscience
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Bioneer Corporation
    • 11.2.10.1. Overview
    • 11.2.10.2. Products & services
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)